PSY52 - Ibrutinib for the treatment of Mantle Cell Lymphoma (MCL): evaluating the correlation between patient-reported outcomes and durability of response in a Phase 2 study.

Authors :: Rule, S.
Goy, A.
Martin, P.
Ramchandren, R.
Alexeeva, J.
Popat, R.
Avivi, I.
Advani, R.
Le Gouill, S.
Horowitz, N.
Yuan, Z.
Kranenburg, B.
Zhuang, S.H.
Deraedt, W.
Rizo, A.
Wildgust, M.
Wang, M.
Source :: Value in Health. May2015, Vol. 18 Issue 3, pA300-A301. 1p.
Publication Year :: 2015

Subjects :: *MANTLE cell lymphoma
*HEALTH outcome assessment
*ANTINEOPLASTIC agents
*RITUXIMAB
*DRUG efficacy
*MEDICATION safety

Full Text Access

Tools